Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 129,682,576
  • Shares Outstanding, K 2,222,114
  • Annual Sales, $ 42,518 M
  • Annual Income, $ -9,015 M
  • 60-Month Beta 0.64
  • Price/Sales 3.02
  • Price/Cash Flow 5.19
  • Price/Book 3.48
Trade BMY with:

Options Overview Details

View History
  • Implied Volatility 24.36%
  • Historical Volatility 17.09%
  • IV Percentile 61%
  • IV Rank 2.01%
  • IV High 437.70% on 12/14/20
  • IV Low 15.86% on 08/06/21
  • Put/Call Vol Ratio 0.47
  • Today's Volume 33,671
  • Volume Avg (30-Day) 32,169
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 663,576
  • Open Int (30-Day) 560,919

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 1.91
  • Number of Estimates 6
  • High Estimate 1.96
  • Low Estimate 1.86
  • Prior Year 1.63
  • Growth Rate Est. (year over year) +17.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.66 +3.00%
on 10/13/21
62.05 -5.95%
on 09/16/21
-3.64 (-5.87%)
since 09/15/21
3-Month
56.66 +3.00%
on 10/13/21
69.75 -16.33%
on 08/23/21
-9.07 (-13.45%)
since 07/15/21
52-Week
56.66 +3.00%
on 10/13/21
69.75 -16.33%
on 08/23/21
-2.06 (-3.41%)
since 10/15/20

Most Recent Stories

More News
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

Bristol Myers Squibb (BMY) closed the most recent trading day at $58.36, moving +1.14% from the previous trading session.

BMY : 58.36 (+1.14%)
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BMY : 58.36 (+1.14%)
Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline

Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.

BIIB : 281.19 (-1.43%)
RHHBY : 48.9200 (+1.39%)
BMY : 58.36 (+1.14%)
PRTA : 63.46 (-2.31%)
Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition

Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.

BMY : 58.36 (+1.14%)
PFE : 41.49 (-0.43%)
MRK : 78.33 (unch)
CLVS : 4.34 (-2.47%)
Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb (NYSE:BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Zeposia (ozanimod) for the...

BMY : 58.36 (+1.14%)
Exelixis (EXEL) Well Poised on Label Expansions of Caboemtyx

The going has been good for Exelixis (EXEL) on label expansions of its lead drug, Cabometyx. The pipeline progress has been encouraging as well.

RHHBY : 48.9200 (+1.39%)
BMY : 58.36 (+1.14%)
BAYRY : 13.9800 (+0.29%)
EXEL : 21.82 (-0.09%)
Oncology Space Rapidly Improving Cancer Therapies in Wake of Operation Warp Speed

VANCOUVER – USA News Group – Oncology data leader COTA recently released a recent survey ...

ONC.TO : 2.75 (+1.85%)
RHHBY : 48.9200 (+1.39%)
BMY : 58.36 (+1.14%)
PFE : 41.49 (-0.43%)
MRK : 78.33 (unch)
ONCY : 2.22 (+1.37%)
Epizyme's (EPZM) Tazverik Aids Growth, Overdependence a Woe

While Epizyme (EPZM) gets a significant boost with the approval of Tazverik for the treatment of follicular lymphoma and epithelioid sarcoma, the sole dependence on Tazverik for growth remains a woe.

RHHBY : 48.9200 (+1.39%)
BMY : 58.36 (+1.14%)
PFE : 41.49 (-0.43%)
EPZM : 4.95 (-1.20%)
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $57.07, marking a +0.02% move from the previous day.

BMY : 58.36 (+1.14%)
Incyte's (INCY) Going Gets Rough Despite Recent Approvals

Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.

BMY : 58.36 (+1.14%)
PFE : 41.49 (-0.43%)
INCY : 65.56 (-0.33%)
ABBV : 109.33 (+0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products. It offers products which includes hematology, oncology, cardiovascular and immunology. Bristol-Myers Squibb Company, formerly known as Bristol-Myers Company, is based in...

See More

Key Turning Points

3rd Resistance Point 59.51
2nd Resistance Point 59.10
1st Resistance Point 58.73
Last Price 58.36
1st Support Level 57.95
2nd Support Level 57.54
3rd Support Level 57.17

See More

52-Week High 69.75
Fibonacci 61.8% 64.75
Fibonacci 50% 63.21
Fibonacci 38.2% 61.66
Last Price 58.36
52-Week Low 56.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar